Morphology and gene expression profiling provide complementary information for mapping cell state.

Cell Painting L1000 benchmark drug discovery high-dimensional profiling images systems biology

Journal

Cell systems
ISSN: 2405-4720
Titre abrégé: Cell Syst
Pays: United States
ID NLM: 101656080

Informations de publication

Date de publication:
16 11 2022
Historique:
received: 18 11 2021
revised: 12 05 2022
accepted: 28 09 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: ppublish

Résumé

Morphological and gene expression profiling can cost-effectively capture thousands of features in thousands of samples across perturbations by disease, mutation, or drug treatments, but it is unclear to what extent the two modalities capture overlapping versus complementary information. Here, using both the L1000 and Cell Painting assays to profile gene expression and cell morphology, respectively, we perturb human A549 lung cancer cells with 1,327 small molecules from the Drug Repurposing Hub across six doses, providing a data resource including dose-response data from both assays. The two assays capture both shared and complementary information for mapping cell state. Cell Painting profiles from compound perturbations are more reproducible and show more diversity but measure fewer distinct groups of features. Applying unsupervised and supervised methods to predict compound mechanisms of action (MOAs) and gene targets, we find that the two assays not only provide a partially shared but also a complementary view of drug mechanisms. Given the numerous applications of profiling in biology, our analyses provide guidance for planning experiments that profile cells for detecting distinct cell types, disease phenotypes, and response to chemical or genetic perturbations.

Identifiants

pubmed: 36395727
pii: S2405-4712(22)00402-1
doi: 10.1016/j.cels.2022.10.001
pmc: PMC10246468
mid: NIHMS1846277
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

911-923.e9

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM122547
Pays : United States
Organisme : NIH HHS
ID : S10 OD026839
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008699
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG006939
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Methods. 2022 Dec;19(12):1550-1557
pubmed: 36344834
Nat Commun. 2023 Apr 8;14(1):1967
pubmed: 37031208
Cell Chem Biol. 2021 Mar 18;28(3):356-370
pubmed: 33592188
Expert Rev Proteomics. 2021 Jul;18(7):503-526
pubmed: 34320887
Front Genet. 2017 Jun 16;8:84
pubmed: 28670325
Toxicol Appl Pharmacol. 2020 Jan 15;389:114876
pubmed: 31899216
Nat Protoc. 2016 Sep;11(9):1757-74
pubmed: 27560178
IEEE Trans Pattern Anal Mach Intell. 1979 Feb;1(2):224-7
pubmed: 21868852
Front Genet. 2020 Feb 05;11:19
pubmed: 32117438
Bioinformatics. 2020 Mar 1;36(5):1607-1613
pubmed: 31608933
Genome Med. 2020 Jan 14;12(1):8
pubmed: 31937368
Nat Rev Drug Discov. 2021 Feb;20(2):145-159
pubmed: 33353986
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
SLAS Technol. 2018 Jun;23(3):243-251
pubmed: 29100480
Nat Biotechnol. 2016 Apr;34(4):419-23
pubmed: 26928769
Cell. 2016 Dec 15;167(7):1853-1866.e17
pubmed: 27984732
Bioinformatics. 2006 Jul 1;22(13):1600-7
pubmed: 16606683
Nat Commun. 2017 Oct 30;8(1):1186
pubmed: 29084964
PLoS One. 2013 Dec 02;8(12):e80999
pubmed: 24312513
Nucleic Acids Res. 2018 Nov 2;46(19):e116
pubmed: 30011038
Cell Syst. 2018 Apr 25;6(4):424-443.e7
pubmed: 29655704
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Sci Transl Med. 2019 Sep 11;11(509):
pubmed: 31511426
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Front Pharmacol. 2015 Jul 28;6:157
pubmed: 26283966
Vision Res. 1997 Dec;37(23):3327-38
pubmed: 9425547
Front Pharmacol. 2019 Feb 19;10:126
pubmed: 30837884
Mol Biol Cell. 2023 May 1;34(5):ar45
pubmed: 36947171
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):10911-6
pubmed: 25024206
Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334
pubmed: 33290552
Exp Mol Pathol. 2020 Feb;112:104347
pubmed: 31759951
Cell Syst. 2018 Jan 24;6(1):13-24
pubmed: 29199020
Sci Rep. 2020 Aug 6;10(1):13262
pubmed: 32764586
Molecules. 2020 Dec 03;25(23):
pubmed: 33287212
Nat Med. 2017 Apr 7;23(4):405-408
pubmed: 28388612
Nat Chem Biol. 2013 Apr;9(4):232-40
pubmed: 23508189
J Microsc. 2014 Dec;256(3):231-6
pubmed: 25228240
Science. 2018 Sep 28;361(6409):1380-1385
pubmed: 30166440
Nat Commun. 2020 Aug 27;11(1):4296
pubmed: 32855387
Science. 2004 Nov 12;306(5699):1194-8
pubmed: 15539606
Bioinformatics. 2011 Apr 15;27(8):1179-80
pubmed: 21349861
Brief Bioinform. 2018 May 1;19(3):506-523
pubmed: 28069634
Nat Methods. 2017 Aug 31;14(9):849-863
pubmed: 28858338
Front Cell Dev Biol. 2018 Apr 20;6:28
pubmed: 29732369
PLoS Comput Biol. 2017 Feb 9;13(2):e1005335
pubmed: 28182661
Mol Biol Cell. 2021 Apr 19;32(9):995-1005
pubmed: 33534641
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
J Biomol Screen. 2013 Dec;18(10):1321-9
pubmed: 24045582
Biol Cybern. 1980;36(4):193-202
pubmed: 7370364
PLoS One. 2015 Mar 04;10(3):e0118432
pubmed: 25738806
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1645-1652
pubmed: 33895079
Nat Rev Drug Discov. 2009 Jul;8(7):567-78
pubmed: 19568283
Commun Biol. 2020 Oct 23;3(1):602
pubmed: 33097816
Drug Discov Today Technol. 2015 Nov;18:1-8
pubmed: 26723886
Curr Opin Chem Biol. 2021 Dec;65:9-17
pubmed: 34023800

Auteurs

Gregory P Way (GP)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO 80045, USA.

Ted Natoli (T)

Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Adeniyi Adeboye (A)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Lev Litichevskiy (L)

Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Andrew Yang (A)

Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Xiaodong Lu (X)

Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Juan C Caicedo (JC)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Beth A Cimini (BA)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Kyle Karhohs (K)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

David J Logan (DJ)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Mohammad H Rohban (MH)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Maria Kost-Alimova (M)

Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Kate Hartland (K)

Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Michael Bornholdt (M)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Srinivas Niranj Chandrasekaran (SN)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Marzieh Haghighi (M)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Erin Weisbart (E)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Shantanu Singh (S)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Aravind Subramanian (A)

Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: asubramanian@dewpointx.com.

Anne E Carpenter (AE)

Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: anne@broadinstitute.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH